Novel nano-membrane technology to enable development of therapeutic antibodies targeting membrane proteins
|Coordinator||Salipro Biotech AB|
|Funding from Vinnova||SEK 500 000|
|Project duration||November 2018 - July 2019|
|Venture||Banbrytande idéer inom industriell utveckling|
|Call||Banbrytande idéer inom industriell utveckling - 2018|
Purpose and goal
The aim of the project is to determine the potential of the Salipro® technology in the context of development of therapeutic antibodies via phage display
Expected results and effects
The project aims at generating membrane protein specific antibodies using the proprietary Salipro® technology. The results will pave an entirely novel way to generate drug target specific antibodies in an industry setting.
Planned approach and implementation
This project is a collaboration between Salipro Biotech AB and the Drug Discovery & Development (DDD) Platform at Science for Life Laboratory (SciLifeLabs). Salipro Biotech AB reconstitutes membrane protein drug targets into the Salipro® nano-membrane particles and SciLifeLabs selects and characterizes drug target specific antibodies.